Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

Bone scan overuse in staging of prostate cancer: an analysis of a Veterans Affairs cohort.

Palvolgyi R, Daskivich TJ, Chamie K, Kwan L, Litwin MS.

Urology. 2011 Jun;77(6):1330-6. doi: 10.1016/j.urology.2010.12.083. Epub 2011 Apr 13.

PMID:
21492911
[PubMed - indexed for MEDLINE]
2.

Editorial comment.

Cooperberg MR.

Urology. 2011 Jun;77(6):1336-7. doi: 10.1016/j.urology.2011.02.010. No abstract available.

PMID:
21624594
[PubMed - indexed for MEDLINE]
3.

Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.

Huncharek M, Muscat J.

Cancer Invest. 1995;13(1):31-5.

PMID:
7530590
[PubMed - indexed for MEDLINE]
4.

Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study.

Al-Ghazo MA, Ghalayini IF, Al-Azab RS, Bani-Hani I, Barham A, Haddad Y.

Int Braz J Urol. 2010 Nov-Dec;36(6):685-91; discussion 691-2.

PMID:
21176275
[PubMed - indexed for MEDLINE]
Free Article
5.

Using prostate-specific antigen to eliminate the staging radionuclide bone scan.

Lee CT, Oesterling JE.

Urol Clin North Am. 1997 May;24(2):389-94.

PMID:
9126236
[PubMed - indexed for MEDLINE]
6.

MRI of the skeleton in prostate cancer staging.

Rydh A, Lundblad M, Ahlström KR, Tavelin B, Stattin P.

Scand J Urol Nephrol. 2003;37(3):222-5.

PMID:
12775281
[PubMed - indexed for MEDLINE]
7.

Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor.

Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, Carroll PR.

J Urol. 2002 Aug;168(2):491-5.

PMID:
12131295
[PubMed - indexed for MEDLINE]
8.

Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.

Huncharek M, Muscat J.

Abdom Imaging. 1996 Jul-Aug;21(4):364-7.

PMID:
8661585
[PubMed - indexed for MEDLINE]
9.

The utilization of Gleason grade as the primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients.

Ritenour CW, Abbott JT, Goodman M, Alazraki N, Marshall FF, Issa MM.

ScientificWorldJournal. 2009 Oct 2;9:1040-5. doi: 10.1100/tsw.2009.113.

PMID:
19802499
[PubMed - indexed for MEDLINE]
Free Article
10.

[The relationship between the serum level of prostate specific antigen and bone and CT scans in the staging of the primary carcinoma of the prostate].

Hoefman E, Hulshof MC, de Reijke TM, Bruijnes E, Redekop WK, van Straalen JP.

Ned Tijdschr Geneeskd. 1998 May 16;142(20):1142-6. Dutch.

PMID:
9623236
[PubMed - indexed for MEDLINE]
11.

Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans.

Murphy GP, Snow PB, Brandt J, Elgamal A, Brawer MK.

Prostate. 2000 Feb 1;42(2):145-9.

PMID:
10617872
[PubMed - indexed for MEDLINE]
12.

Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer?

Vijayakumar V, Vijayakumar S, Quadri SF, Blend MJ.

Am J Clin Oncol. 1994 Oct;17(5):432-6.

PMID:
7522394
[PubMed - indexed for MEDLINE]
13.

Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications.

Oesterling JE.

Urol Clin North Am. 1993 Nov;20(4):705-11.

PMID:
7505979
[PubMed - indexed for MEDLINE]
14.

Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital.

O'Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP.

BJU Int. 2003 Nov;92(7):685-9.

PMID:
14616446
[PubMed - indexed for MEDLINE]
15.

Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.

Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE.

J Urol. 1991 Feb;145(2):313-8.

PMID:
1703240
[PubMed - indexed for MEDLINE]
16.

When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer?

Pal RP, Thiruudaian T, Khan MA.

Asian J Androl. 2008 Nov;10(6):890-5. doi: 10.1111/j.1745-7262.2008.00427.x.

PMID:
18958353
[PubMed - indexed for MEDLINE]
Free Article
17.

The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.

Rudoni M, Antonini G, Favro M, Baroli A, Brambilla M, Cardani G, Ciardi L, Sacchetti GM, Inglese E.

Eur J Nucl Med. 1995 Mar;22(3):207-11.

PMID:
7540551
[PubMed - indexed for MEDLINE]
18.

Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.

Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ.

BJU Int. 2001 Aug;88(3):226-30.

PMID:
11488734
[PubMed - indexed for MEDLINE]
19.

The value of pretreatment clinical and biochemical parameters in staging and prognostic stratification of patients with newly diagnosed prostate carcinoma.

Stokkel MP, Zwinderman AH, Zwartendijk J, Pauwels EK, Van Eck-Smit BL.

Int J Biol Markers. 1998 Apr-Jun;13(2):70-6.

PMID:
9803354
[PubMed - indexed for MEDLINE]
20.

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.

Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, Goldenberg SL, Sullivan LD.

Urology. 1996 May;47(5):708-12.

PMID:
8650870
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk